

# Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022

<https://marketpublishers.com/r/GD7E0CF43D4EN.html>

Date: March 2017

Pages: 222

Price: US\$ 2,400.00 (Single User License)

ID: GD7E0CF43D4EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022” report gives comprehensive insight on clinical and non-clinical aspects involved in the development and integration of immune check point inhibitors as main streamline drugs in the immunotherapy treatment. Report helps to identify the basic classification and molecular mechanism of action of immune check point inhibitors drugs available in the market and in the clinical pipeline. Currently there are 4 Immune Check Point Inhibitors drugs commercially available in the market and more than 70 drugs in clinical pipeline.

Immunotherapy represents a paradigm shift in cancer therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity.

Immune checkpoint inhibitors are the type of drugs which blocks the certain proteins made by some types of immune system cells, such as T cells and some cancer cells. These proteins help to keep the immune responses in check and keep the T cells from killing the cancer cells. When the proteins are blocked, the brakes on the immune system are released and T cells are able to kill the cancer cell better. The checkpoint proteins which found on T cells or cancer cells include the PD-1/PD-L1 and CTLA-4/B7-1/B7-2. Some immune checkpoint inhibitors are used to treat the cancer. Checkpoint proteins, such as PD-L1 on tumor cells and PD-1 on T cells, help to keep the immune responses in check. The binding of PD-L1 to PD-1 keeps T cells from killing

tumor cells in the body. Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1) allows the T cells to kill tumor cells.

The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab were approved by FDA and are indicated for the treatment of squamous non-small cell lung cancer and metastatic melanoma, respectively. Several other anti PD-1 drugs are in late stage clinical trials and are expected to achieve the regulatory approval in the near future. Moreover, the anti PD-L1, antibody which targets the tumor cells rather than the T cells is also being studied and tested.

Immune checkpoint inhibitors appears to offer an advantage compared with standard cytotoxic chemotherapy and produces high response rates, durable response and the survival curves which indicate the sustained remission of long therapy which has been completed. Safety with the new therapies is of concern since the immune system is being suppressed by the cancer and the immune checkpoint inhibitors are turning the suppressed immune system. There are several factors of immune checkpoint inhibitors which help in the growth of market and in future help to continue the impact of immune checkpoint inhibitors in the market.

“Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022” report highlights:

Introduction & Mechanism of Action of Immune Checkpoint Inhibitors

CTLA 4, PD-1 & PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints

Biomarkers Associated with Immune Checkpoint Inhibitors

Combination Approaches with Immune Checkpoint Inhibitors

Global Immune Checkpoint Inhibitors Clinical Pipeline

Future Potential of Immune Checkpoint Inhibitors

## Contents

### **1. IMMUNE CHECKPOINT INHIBITORS- INTRODUCTION TO NEXT GENERATION CANCER IMMUNOTHERAPY**

#### 1.1 Overview

#### 1.2 History- From Tragedy to Breakthrough

### **2. MAJOR IMMUNE CHECKPOINTS PROTEINS**

#### 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development

#### 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development

### **3. MECHANISM OF ACTION OF IMMUNE CHECKPOINT INHIBITORS**

#### 3.1 Cytotoxic T lymphocyte Antigen-4 (CTLA-4)

#### 3.1 Programed Death Protein-1 (PD1)

### **4. CTLA 4 INHIBITION APPROVED DRUGS TO TARGET IMMUNE CHECKPOINTS**

#### 4.1 Ipilimumab (Yervoy: Melanoma)

### **5. PD-1 & PD-L1 INHIBITION APPROVED DRUGS TO TARGET IMMUNE CHECKPOINTS**

#### 5.1 Nivolumab (Opdivo: Hodgkin Lymphoma, Urothelial Carcinoma & NSCLC)

#### 5.2 Pembrolizumab (Keytruda: Melanoma & NSCLC)

#### 5.3 Atezolizumab (Tecentriq: Solid Tumors)

### **6. BIOMARKERS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS**

#### 6.1 Predictive Biomarkers to Anti-CTLA

#### 6.2 Predictive Biomarker to Anti-PD

### **7. COMBINATION APPROACHES WITH IMMUNE CHECKPOINT INHIBITORS**

#### 7.1 Combination with Conventional Methods

##### 7.1.1 Chemotherapy

##### 7.1.2 Targeted Therapies

- 7.1.3 Radiotherapy
- 7.2 Combination with Cancer Vaccines
  - 7.2.1 Peptide Vaccines
  - 7.2.2 Cellular Vaccines
  - 7.2.3 Oncolytic Viruses

## **8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET**

## **9. GLOBAL IMMUNE CHECKPOINT INHIBITORS CLINICAL PIPELINE**

- 9.1 CTLA-4-Inhibitors Pipeline Overview
- 9.2 PD-1-Protein-Inhibitors Pipeline Overview
- 9.3 PD-1-Protein-Inhibitors Pipeline Overview

## **10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET DYNAMICS**

- 10.1 Favorable Parameters
- 10.2 Challenges to Market Growth

## **11. FUTURE POTENTIAL OF IMMUNE CHECKPOINT INHIBITORS**

- 11.1 Current Therapeutic Eminence
- 11.2 Upcoming Market Opportunities

## **12. PDL1-PROTEIN-INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 12.1 Research
- 12.2 Preclinical
- 12.3 Clinical
- 12.4 Phase-I
- 12.5 Phase-I/II
- 12.6 Preregistration

## **13. MARKETED PDL1-PROTEIN-INHIBITORS CLINICAL INSIGHT BY COMPANY & PHASE**

- 13.1 Pembrolizumab (Keytruda)
- 13.2 Atezolizumab (TECENTRIQ)

## **14. CTLA-4-INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 14.1 Research
- 14.2 Preclinical
- 14.3 Phase-I
- 14.4 Phase-III

## **15. MARKETED CTLA-4-INHIBITORS CLINICAL INSIGHT BY COMPANY, PHASE & INDICATION**

- 15.1 Ipilimumab (Yervoy)

## **16. PD-1-PROTEIN-INHIBITORS CLINICAL PIPELINE BY COMPANY, PHASE & INDICATION**

- 16.1 Research
- 16.2 Preclinical
- 16.3 Phase-I
- 16.4 Phase-I/II
- 16.5 Phase-II
- 16.6 Phase-II/III

## **17. MARKETED PD-1-PROTEIN-INHIBITORS CLINICAL INSIGHT BY COMPANY & PHASE**

- 17.1 Pembrolizumab (Keytruda)

## **18. COMPETITIVE LANDSCAPE**

- 18.1 Advaxis
- 18.2 Agenus
- 18.3 Amgen
- 18.4 Bristol Myers Squibb
- 18.5 Faron Pharmaceuticals
- 18.6 Genentech
- 18.7 Genocera
- 18.8 Incyte Corporation

- 18.9 Innate Pharma
- 18.10 Kite Pharma
- 18.11 MacroGenics
- 18.12 Merck
- 18.13 NewLink Genetics Corp
- 18.14 Sorrento Therapeutics
- 18.15 TG Therapeutics

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: History of Immune Checkpoint Inhibitors
- Figure 2-1: Types of Immune Checkpoint Proteins
- Figure 2-2: Cytotoxic T Cell Lymphocyte in Cancer Development
- Figure 2-3: Programmed Death Protein in Cancer Development
- Figure 3-1: Mechanism of Action of Cytotoxic T lymphocyte Antigen-
- Figure 3-2: Mechanism of Action of Programmed Death Protein-1
- Figure 4-1: Categorization of Approved Drugs to Target Immune Checkpoints
- Figure 4-2: Yervoy – Global Revenue (US\$ Million), 2015 – 2016 & 2022
- Figure 4-3: Yervoy – US Revenue (US\$ Million), 2015 & 2016
- Figure 5-1: Opdivo – Global Revenue (US\$ Million), 2015 & 2016 & 2022
- Figure 5-2: Opdivo – US Revenue (US\$ Million), 2015 & 2016
- Figure 5-3: Keytruda – Global Revenue (US\$ Million), 2015-2016 & 2022
- Figure 5-4: Tecentriq – Global Revenue (US\$ Million), 2015-2022
- Figure 7-1: Combination Approaches with Immune Checkpoint Inhibitors used in Treatment
- Figure 8-1: Global - Share of Immune Checkpoint Inhibitors in Cancer Immunotherapy Market, 2015-2022 (%)
- Figure 8-2: Global - Immune Checkpoint Inhibitors Market (US\$, Billion), 2016-2022
- Figure 9-1: CTLA-4-Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
- Figure 9-2: CTLA-4-Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
- Figure 9-3: PD-1-Protein-Inhibitors Pipeline by Phase (%), 2017 till 2022
- Figure 9-4: PD-1-Protein-Inhibitors Pipeline by Phase (Number), 2017 till 2022
- Figure 9-5: PD-1-Protein-Inhibitors Pipeline by Phase (%), 2017 till 2022
- Figure 9-6: PD-1-Protein-Inhibitors Pipeline by Phase (Number), 2017 till 2022
- Figure 10-1: Accelerating Parameters for Global Immune Checkpoint Inhibitors Market
- Figure 10-2: Barriers to Global Immune Checkpoint Inhibitors Market Growth

## List Of Tables

### LIST OF TABLES

Table 6-1: Possible Biomarkers Used in Treatment with Anti-CTLA-4

Table 6-2: Potential Biomarker Used in Treatment with Anti-PD-1

Table 10-1: Immune Checkpoint Inhibitors Marketed & Pipeline



## I would like to order

Product name: Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022

Product link: <https://marketpublishers.com/r/GD7E0CF43D4EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD7E0CF43D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970